Clinical Trials Logo

Classic Kaposi Sarcoma clinical trials

View clinical trials related to Classic Kaposi Sarcoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05846724 Not yet recruiting - Kaposi Sarcoma Clinical Trials

Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma

PULSAR
Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

Phase II study of Pembrolizumab plus Lenvatinib in relapsed/refractory Classic Kaposi Sarcoma (CKS). After a screening phase of up to 28 days, each participant will receive study intervention of pembrolizumab plus lenvatinib until reaching a discontinuation criterion: disease progression; unacceptable adverse event(s) (AEs); intercurrent illness that prevents further administration of treatment; participant withdraws consent; pregnancy of participant; non-compliance with study intervention or procedure requirements; or administrative reasons requiring cessation of treatment. After the end of treatment, each participant will be followed for the occurrence of AEs and spontaneously reported pregnancy. Participants who discontinue for reasons other than PD will have post-treatment follow-up for disease status until PD is documented clinically by a team of committed dermatologists, and/or radiographically per RECIST 1.1, a non-study anticancer treatment is initiated, consent is withdrawn, or the participant becomes lost to follow-up. All participants will be followed for overall survival (OS) until death, withdrawal of consent,lost to follow-up, or the end of the study. The end of the study will be when the last participant completes the last study-related telephone call or visit,withdraws from the study, or is lost to follow-up.

NCT ID: NCT03219671 Recruiting - Clinical trials for Classic Kaposi Sarcoma

Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Start date: April 1, 2018
Phase: Phase 2
Study type: Interventional

A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)

NCT ID: NCT00521092 Withdrawn - Clinical trials for AIDS-related Kaposi Sarcoma

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Start date: January 2009
Phase: Phase 2
Study type: Interventional

Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.